Reports
Reports
Analyst Viewpoint
Rise in number of children with disorders and diseases, such as allergies, asthma and other respiratory disorders, high blood pressure, obesity, mental disorders, and infectious diseases, is driving the global pediatric health care products and services industry growth. Moreover, increase in awareness levels about pediatric health and rise in number of programs targeted toward safeguarding the interests and rights of the children are anticipated to propel the demand for pediatric products and services in the next few year.
Government programs and initiatives that promote comprehensive development in children are expected to help improve the overall well-being of children and boost the pediatric health care products and services market during the forecast period. Furthermore, increase in demand for pediatric healthcare across the globe is expected to create opportunities for leading pharmaceutical manufacturers to develop new treatments and technologies that can improve the health outcomes for children.
Increase in burden of diseases and disorders, such as infectious diseases, allergies, and other respiratory conditions, among children and rise in emphasis on newborn screening programs focused on detecting various health conditions in infants are expected to drive the pediatric health care products and services market value.
One of the prominent pediatric healthcare products and services market trends is the growing emphasis on funding, drug and device development, physician-scientist training, and diversity. Addressing early-life diseases and adverse childhood experiences has lifelong benefits for individuals, families, and communities. This may also limit or even prevent numerous chronic adult-onset diseases that originate in early life.
Significant increase in prevalence of disorders among neonates and babies is prompting major pharmaceutical companies to develop effective pediatric drugs and therapies. Moreover, surge in awareness and diagnosis of pediatric disorders is driving the number of children who require special care, which in turn is boosting the demand for child care services.
Growing burden of diseases, viral infections, and malnutrition cases every year is a key factor boosting the pediatric healthcare products and services market demand. Additionally, rise in need for care for chronic illness, diarrhea, and injury-related sickness among children is boosting the demand for pediatric wellness solutions and children's healthcare services.
Technological advancements and a growing focus on preventive care are expected to fuel the pediatric healthcare products and services market revenue during the forecast period. Furthermore, surge in unhealthy lifestyle habits among children and rise in obese pediatric population is prompting leading drug manufacturers to focus on expanding their pediatric wellness offerings.
In 2020, children accounted for approximately 23% of the U.S. population and about 10% of all public healthcare spending. Increase in funding for research on pediatric disorders, especially in countries such as the U.S., the U.K., and Germany, is expected to result in new treatment options for the management of various ailments in children.
Countries across the globe are partnering with the prominent players in the pharmaceutical industry to develop novel drugs that address concerns arising due to resistance developed by microorganisms toward antibiotic drugs. These initiatives are anticipated to boost investments for the development of new and improved medicines to be used for combating antibiotic-resistant bacteria.
Major pharmaceutical companies are focusing on new product launches along with expanding the indications of existing drugs for pediatric patients in order to tap into the large unmet needs. These factors are likely to positively impact the pediatric health care products and services market forecast during the forecast period.
North America accounted for a notable pediatric health care products and services market share in 2022 due to rise in government funding and growth in demand for pediatric healthcare services. Furthermore, the market in North America is estimated to grow considerably in the next few years due to rise in number of pediatric patients suffering from various health conditions such as autism, respiratory disorders, cerebral palsy, and muscular atrophy.
The pediatric health care products & services industry growth is Asia Pacific is anticipated to be rapid during the forecast period due to increase in number of awareness campaigns regarding pediatric ailments in countries such as India, China, and Philippines. Moreover, rise in spending on pediatric and public healthcare is crucial for the development of new treatments and technologies that can improve the health outcomes for children.
According to the latest pediatric health care products and services market analysis, prominent companies operating in the industry are offering a diverse product portfolio along with a strong global distribution system. Key players are also adopting the latest technologies to develop effective drugs and devices, which in turn is likely to strengthen their geographical reach and customer base.
AstraZeneca Plc, Boehringer Ingelheim Plc, Eisai Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Mylan N.V., Novartis AG, Pediapharm, Inc., Pfizer, Inc., and Sanofi S.A. are a few prominent entities operating in the global pediatric health care products and services market.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 95.6 Bn |
| Forecast (Value) in 2031 | More than US$ 173.5 Bn |
| Growth Rate (CAGR) | 6.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global market was valued at US$ 95.6 Bn in 2022
It is projected to grow at a CAGR of 6.9% from 2023 to 2031
Rise in incidence of infectious illnesses in children and increase in expenditure on pediatric healthcare
The allergy and respiratory disorders segment accounted for the largest share in 2022
North America is likely to be a dominant region in the next few years.
AstraZeneca plc, Boehringer Ingelheim plc, Eisai Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Mylan N.V., Novartis AG, Pediapharm, Inc., Pfizer, Inc., and Sanofi S.A.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pediatric Health Care Products and Services Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pediatric Health Care Products and Services Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Disease/Disorder/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Disease/Disorder
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease/Disorder, 2023–2031
6.3.1. Allergy and Respiratory
6.3.2. Cancer
6.3.3. Cardiovascular
6.3.4. Central Nervous System
6.3.5. Gastrointestinal
6.3.6. Hormonal Imbalance
6.3.7. Infections
6.3.8. Others
6.4. Market Attractiveness, by Disease/Disorder
7. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2023–2031
7.3.1. Antibiotics
7.3.2. Analgesics
7.3.3. Anti-asthmatics
7.3.4. Antidepressants
7.3.5. Antidiarrheal
7.3.6. Antifungal
7.3.7. Anti-histamines
7.3.8. Antihypertensives
7.3.9. Anti-metabolites
7.3.10. Anti-neoplastic Antibiotics
7.3.11. Antipsychotics
7.3.12. Others
7.3.13. Market Attractiveness, by Drug Class
8. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Service
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Service, 2023–2031
8.3.1. Child Psychiatry Services
8.3.2. Gastrointestinal Services
8.3.3. Pediatric Cancer Services
8.3.4. Pediatric Diabetes Services
8.3.5. Pediatric Heart Services
8.3.6. Others
8.4. Market Attractiveness, by Service
9. Global Pediatric Health Care Products and Services Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Pediatric Health Care Products and Services Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Disease/Disorder, 2023–2031
10.2.1. Allergy and Respiratory
10.2.2. Cancer
10.2.3. Cardiovascular
10.2.4. Central Nervous System
10.2.5. Gastrointestinal
10.2.6. Hormonal Imbalance
10.2.7. Infections
10.2.8. Others
10.3. Market Attractiveness, by Disease/Disorder
10.4. Market Value Forecast, by Drug Class, 2023–2031
10.4.1. Antibiotics
10.4.2. Analgesics
10.4.3. Anti-asthmatics
10.4.4. Antidepressants
10.4.5. Antidiarrheal
10.4.6. Antifungal
10.4.7. Anti-histamines
10.4.8. Antihypertensives
10.4.9. Anti-metabolites
10.4.10. Anti-neoplastic Antibiotics
10.4.11. Antipsychotics
10.4.12. Others
10.5. Market Attractiveness, by Drug Class
10.6. Market Value Forecast, by Service, 2023–2031
10.6.1. Child Psychiatry Services
10.6.2. Gastrointestinal Services
10.6.3. Pediatric Cancer Services
10.6.4. Pediatric Diabetes Services
10.6.5. Pediatric Heart Services
10.6.6. Others
10.7. Market Attractiveness, by Service
10.8. Market Value Forecast, by Country, 2023–2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Disease/Disorder
10.9.2. By Drug Class
10.9.3. By Service
10.9.4. By Country
11. Europe Pediatric Health Care Products and Services Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease/Disorder, 2023–2031
11.2.1. Allergy and Respiratory
11.2.2. Cancer
11.2.3. Cardiovascular
11.2.4. Central Nervous System
11.2.5. Gastrointestinal
11.2.6. Hormonal Imbalance
11.2.7. Infections
11.2.8. Others
11.3. Market Attractiveness, by Disease/Disorder
11.4. Market Value Forecast, by Drug Class, 2023–2031
11.4.1. Antibiotics
11.4.2. Analgesics
11.4.3. Anti-asthmatics
11.4.4. Antidepressants
11.4.5. Antidiarrheal
11.4.6. Antifungal
11.4.7. Anti-histamines
11.4.8. Antihypertensives
11.4.9. Anti-metabolites
11.4.10. Anti-neoplastic Antibiotics
11.4.11. Antipsychotics
11.4.12. Others
11.5. Market Attractiveness, by Drug Class
11.6. Market Value Forecast, by Service, 2023–2031
11.6.1. Child Psychiatry Services
11.6.2. Gastrointestinal Services
11.6.3. Pediatric Cancer Services
11.6.4. Pediatric Diabetes Services
11.6.5. Pediatric Heart Services
11.6.6. Others
11.7. Market Attractiveness, by Service
11.8. Market Value Forecast, by Country/Sub-region, 2023–2031
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Market Attractiveness Analysis
11.9.1. By Disease/Disorder
11.9.2. By Drug Class
11.9.3. By Service
11.9.4. By Country/Sub-region
12. Asia Pacific Pediatric Health Care Products and Services Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease/Disorder, 2023–2031
12.2.1. Allergy and Respiratory
12.2.2. Cancer
12.2.3. Cardiovascular
12.2.4. Central Nervous System
12.2.5. Gastrointestinal
12.2.6. Hormonal Imbalance
12.2.7. Infections
12.2.8. Others
12.3. Market Attractiveness, by Disease/Disorder
12.4. Market Value Forecast, by Drug Class, 2023–2031
12.4.1. Antibiotics
12.4.2. Analgesics
12.4.3. Anti-asthmatics
12.4.4. Antidepressants
12.4.5. Antidiarrheal
12.4.6. Antifungal
12.4.7. Anti-histamines
12.4.8. Antihypertensives
12.4.9. Anti-metabolites
12.4.10. Anti-neoplastic Antibiotics
12.4.11. Antipsychotics
12.4.12. Others
12.5. Market Attractiveness, by Drug Class
12.6. Market Value Forecast, by Service, 2023–2031
12.6.1. Child Psychiatry Services
12.6.2. Gastrointestinal Services
12.6.3. Pediatric Cancer Services
12.6.4. Pediatric Diabetes Services
12.6.5. Pediatric Heart Services
12.6.6. Others
12.7. Market Attractiveness, by Service
12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Disease/Disorder
12.9.2. By Drug Class
12.9.3. By Service
12.9.4. By Country/Sub-region
13. Latin America Pediatric Health Care Products and Services Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease/Disorder, 2023–2031
13.2.1. Allergy and Respiratory
13.2.2. Cancer
13.2.3. Cardiovascular
13.2.4. Central Nervous System
13.2.5. Gastrointestinal
13.2.6. Hormonal Imbalance
13.2.7. Infections
13.2.8. Others
13.3. Market Attractiveness, by Disease/Disorder
13.4. Market Value Forecast, by Drug Class, 2023–2031
13.4.1. Antibiotics
13.4.2. Analgesics
13.4.3. Anti-asthmatics
13.4.4. Antidepressants
13.4.5. Antidiarrheal
13.4.6. Antifungal
13.4.7. Anti-histamines
13.4.8. Antihypertensives
13.4.9. Anti-metabolites
13.4.10. Anti-neoplastic Antibiotics
13.4.11. Antipsychotics
13.4.12. Others
13.5. Market Attractiveness, by Drug Class
13.6. Market Value Forecast, by Service, 2023–2031
13.6.1. Child Psychiatry Services
13.6.2. Gastrointestinal Services
13.6.3. Pediatric Cancer Services
13.6.4. Pediatric Diabetes Services
13.6.5. Pediatric Heart Services
13.6.6. Others
13.7. Market Attractiveness, by Service
13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Disease/Disorder
13.9.2. By Drug Class
13.9.3. By Service
13.9.4. By Country/Sub-region
14. Middle East & Africa Pediatric Health Care Products and Services Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease/Disorder, 2023–2031
14.2.1. Allergy and Respiratory
14.2.2. Cancer
14.2.3. Cardiovascular
14.2.4. Central Nervous System
14.2.5. Gastrointestinal
14.2.6. Hormonal Imbalance
14.2.7. Infections
14.2.8. Others
14.3. Market Attractiveness, by Disease/Disorder
14.4. Market Value Forecast, by Drug Class, 2023–2031
14.4.1. Antibiotics
14.4.2. Analgesics
14.4.3. Anti-asthmatics
14.4.4. Antidepressants
14.4.5. Antidiarrheal
14.4.6. Antifungal
14.4.7. Anti-histamines
14.4.8. Antihypertensives
14.4.9. Anti-metabolites
14.4.10. Anti-neoplastic Antibiotics
14.4.11. Antipsychotics
14.4.12. Others
14.5. Market Attractiveness, by Drug Class
14.6. Market Value Forecast, by Service, 2023–2031
14.6.1. Child Psychiatry Services
14.6.2. Gastrointestinal Services
14.6.3. Pediatric Cancer Services
14.6.4. Pediatric Diabetes Services
14.6.5. Pediatric Heart Services
14.6.6. Others
14.7. Market Attractiveness, by Service
14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Disease/Disorder
14.9.2. By Drug Class
14.9.3. By Service
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca plc
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Disease/Disorder Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Boehringer Ingelheim GmbH
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Disease/Disorder Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Eisai Co., Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Disease/Disorder Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Gilead Sciences, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Disease/Disorder Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. GlaxoSmithKline plc
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Disease/Disorder Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Merck & Co., Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Disease/Disorder Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Mylan N.V.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Disease/Disorder Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Novartis AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Disease/Disorder Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Pediapharm, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Disease/Disorder Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Pfizer, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Disease/Disorder Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Sanofi S.A.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Disease/Disorder Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
List of Tables
Table 01: Global Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Disease/Disorder, 2023–2031
Table 02: Global Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 03: Global Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Service, 2023–2031
Table 04: Global Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Region, 2023–2031
Table 05: North America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Country, 2023–2031
Table 06: North America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Disease/Disorder, 2023–2031
Table 07: North America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 08: North America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Service, 2023–2031
Table 09: Europe Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Europe Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Disease/Disorder, 2023–2031
Table 11: Europe Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 12: Europe Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Service, 2023–2031
Table 13: Asia Pacific Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Asia Pacific Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Disease/Disorder, 2023–2031
Table 15: Asia Pacific Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 16: Asia Pacific Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Service, 2023–2031
Table 17: Latin America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 18: Latin America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Disease/Disorder, 2023–2031
Table 19: Latin America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 20: Latin America Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Service, 2023–2031
Table 21: Middle East & Africa Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 22: Middle East & Africa Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Disease/Disorder, 2023–2031
Table 23: Middle East & Africa Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Drug Class, 2023–2031
Table 24: Middle East & Africa Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast, by Service, 2023–2031
List of Figures
Figure 01: Global Pediatric Health Care Products and Services Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Pediatric Health Care Products and Services Market Revenue (US$ Mn), by Disease/Disorder, 2022
Figure 03: Global Pediatric Health Care Products and Services Market Value Share, by Disease/Disorder, 2022
Figure 04: Global Pediatric Health Care Products and Services Market Revenue (US$ Mn), by Drug Class, 2022
Figure 05: Global Pediatric Health Care Products and Services Market Value Share, by Drug Class, 2022
Figure 06: Global Pediatric Health Care Products and Services Market Revenue (US$ Mn), by Service, 2022
Figure 07: Global Pediatric Health Care Products and Services Market Value Share, by Service, 2022
Figure 08 Global Pediatric Health Care Products and Services Market Value Share, by Region, 2022
Figure 09: Global Pediatric Health Care Products and Services Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Pediatric Health Care Products and Services Market Value Share Analysis, by Disease/Disorder, 2022 and 2031
Figure 11: Global Pediatric Health Care Products and Services Market Attractiveness Analysis, by Disease/Disorder, 2023-2031
Figure 12: Global Pediatric Health Care Products and Services Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 13: Global Pediatric Health Care Products and Services Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 14: Global Pediatric Health Care Products and Services Market Value Share Analysis, by Service, 2022 and 2031
Figure 15: Global Pediatric Health Care Products and Services Market Attractiveness Analysis, by Service, 2023-2031
Figure 16: Global Pediatric Health Care Products and Services Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Pediatric Health Care Products and Services Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Pediatric Health Care Products and Services Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 19: North America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Pediatric Health Care Products and Services Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Pediatric Health Care Products and Services Market Value Share Analysis, by Disease/Disorder, 2022 and 2031
Figure 22: North America Pediatric Health Care Products and Services Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 23: North America Pediatric Health Care Products and Services Market Value Share Analysis, by Service, 2022 and 2031
Figure 24: North America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Disease/Disorder, 2023–2031
Figure 25: North America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 26: North America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Service, 2023–2031
Figure 27: Europe Pediatric Health Care Products and Services Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 28: Europe Pediatric Health Care Products and Services Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Pediatric Health Care Products and Services Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Pediatric Health Care Products and Services Market Value Share Analysis, by Disease/Disorder, 2022 and 2031
Figure 31: Europe Pediatric Health Care Products and Services Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 32: Europe Pediatric Health Care Products and Services Market Value Share Analysis, by Service, 2022 and 2031
Figure 33: Europe Pediatric Health Care Products and Services Market Attractiveness Analysis, by Disease/Disorder, 2023–2031
Figure 34: Europe Pediatric Health Care Products and Services Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 35: Europe Pediatric Health Care Products and Services Market Attractiveness Analysis, by Service, 2023–2031
Figure 36: Asia Pacific Pediatric Health Care Products and Services Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 37: Asia Pacific Pediatric Health Care Products and Services Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Pediatric Health Care Products and Services Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Pediatric Health Care Products and Services Market Value Share Analysis, by Disease/Disorder, 2022 and 2031
Figure 40: Asia Pacific Pediatric Health Care Products and Services Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 41: Asia Pacific Pediatric Health Care Products and Services Market Value Share Analysis, by Service, 2022 and 2031
Figure 42: Asia Pacific Pediatric Health Care Products and Services Market Attractiveness Analysis, by Disease/Disorder, 2022–2031
Figure 43: Asia Pacific Pediatric Health Care Products and Services Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 44: Asia Pacific Pediatric Health Care Products and Services Market Attractiveness Analysis, by Service, 2023–2031
Figure 45: Latin America Pediatric Health Care Products and Services Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 46: Latin America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Pediatric Health Care Products and Services Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Pediatric Health Care Products and Services Market Value Share Analysis, by Disease/Disorder, 2022 and 2031
Figure 49: Latin America Pediatric Health Care Products and Services Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 50: Latin America Pediatric Health Care Products and Services Market Value Share Analysis, by Service, 2022 and 2031
Figure 51: Latin America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Disease/Disorder, 2023–2031
Figure 52: Latin America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 53: Latin America Pediatric Health Care Products and Services Market Attractiveness Analysis, by Service, 2023–2031
Figure 54: Middle East & Africa Pediatric Health Care Products and Services Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 55: Middle East & Africa Pediatric Health Care Products and Services Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Pediatric Health Care Products and Services Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Pediatric Health Care Products and Services Market Value Share Analysis, by Disease/Disorder, 2022 and 2031
Figure 58: Middle East & Africa Pediatric Health Care Products and Services Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 59: Middle East & Africa Pediatric Health Care Products and Services Market Value Share Analysis, by Service, 2022 and 2031
Figure 60: Middle East & Africa Pediatric Health Care Products and Services Market Attractiveness Analysis, by Disease/Disorder, 2023–2031
Figure 61: Middle East & Africa Pediatric Health Care Products and Services Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 62: Middle East & Africa Pediatric Health Care Products and Services Market Attractiveness Analysis, by Service, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pediatric Health Care Products and Services Market